CDAK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 May 2024 @ 16:00):

Stats
Today's Volume	14.21M
Average Volume	0.00
Market Cap	2.83M
EPS	$0 ( 2023-11-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0210 (105.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-30	Howze Yalonda	Sell	1 628	Common Stock
2023-03-29	Sathyanarayanan Sriram	Sell	11 762	Common Stock
2023-03-28	Konstantinov Konstantin	Sell	7 432	Common Stock
2023-03-28	Konstantinov Konstantin	Sell	1 932	Common Stock
2023-03-28	Bain Linda	Sell	13 412	Common Stock

INSIDER POWER
92.28
Last 100 transactions
Buy: 14 044 661 \| Sell: 316 076

Volume Correlation

Long: -0.25 (neutral)

Short: 0.79 (moderate)

Signal:(35.08) Neutral

Codiak BioSciences, Inc. Correlation

10 Most Positive Correlations
VORB	0.949
PEAR	0.939
DTEA	0.926
PHCF	0.91
BBBY	0.848
PLXP	0.837

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Codiak BioSciences, Inc. Correlation - Currency/Commodity

-0.83
( strong negative )

-0.76
( moderate negative )

0.82
( strong )

-0.93
( very strong negative )

0.30
( neutral )

Codiak BioSciences, Inc. Financials

Annual	2021
Revenue:	$22.94M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.664

FY	2021
Revenue:	$22.94M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.664

FY	2020
Revenue:	$2.92M
Gross Profit:	$2 915.00 (0.10 %)
EPS:	$-16.18

FY	2019
Revenue:	$388 000
Gross Profit:	$0.00 (0.00 %)
EPS:	$-5.96

Financial Reports:

No articles found.

Codiak BioSciences, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Codiak BioSciences, Inc.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.